Ocugen, Inc. (OCGN) stock
OCGNNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
$0.76−0.02 (-2.11%)
Close on Nov 17, 2026Market cap $256.60MP/E –Yield –
Ocugen price to sales ratio
The price-to-sales ratio is market cap divided by revenue over the trailing twelve months.
Ocugen's price to sales ratio was 84.3× on Jan 30, 2026, against 44.9× a year earlier. Over the last 4 years it ranged from 18.0× to 487.9×, with a median of 60.4×.
Price to Sales Ratio at the end of each year
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| 2026 | Jan 30, 2026 | 84.3× | +5.8 |
| 2025 | Dec 31, 2025 | 78.5× | +28.8 |
| 2024 | Dec 31, 2024 | 49.7× | +22.9 |
| 2023 | Dec 29, 2023 | 26.8× | −148.3 |
| 2022 | Dec 30, 2022 | 175.1× | – |
See a number that looks wrong?